Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTPS1 | P17812 | 12/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.40 |
| ▸ | CTPS2 | Q9NRF8 | 2/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24369756 | 0.86 | CTPS1 (0.49) | CTPS1CA12CA1CA2CA9 | |
| SCHEMBL24088639 | 0.82 | CA12 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL24088640 | 0.82 | L3MBTL1 (0.43) | CTPS1CA12CA1CA2CA9 | |
| SCHEMBL24088754 | 0.81 | CA12 (0.46) | CTPS1CA12CA1CA2CA9 | |
| SCHEMBL21391994 | 0.80 | CHEK1 (0.56) | CTPS1CHEK1 | |
| SCHEMBL25098529 | 0.80 | CTPS1 (0.45) | CTPS1CA1CA2CHEK1SCN10A | |
| SCHEMBL29253937 | 0.80 | PDK2 (0.45) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30416354 | 0.79 | CHEK1 (0.50) | CTPS1CHEK1 | |
| SCHEMBL21392100 | 0.77 | CA12 (0.42) | CTPS1CA12CA1CA2CA9 | |
| SCHEMBL21392102 | 0.77 | CTPS1 (0.47) | CTPS1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20250263407-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-08-21 | — | — | US | disclosed |
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20210380575-A1 | COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CA12 247/4885CA1 804/4885 |
| US-20250263407-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885CA12 195/4885CA1 629/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885CA12 195/4885CA1 629/4885 |
| US-20210380575-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP1B1 | CTPS1 2556/4885CA12 247/4885CA1 804/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885CA12 195/4885CA1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.